Targeting human central nervous system protein kinases: An isoform selective p38 alpha MAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models.
Roy, S.M., Grum-Tokars, V.L., Schavocky, J.P., Saeed, F., Staniszewski, A., Teich, A.F., Arancio, O., Bachstetter, A.D., Webster, S.J., Van Eldik, L.J., Minasov, G., Anderson, W.F., Pelletier, J.C., Watterson, D.M.(2015) ACS Chem Neurosci 6: 666-680
- PubMed: 25676389 
- DOI: 10.1021/acschemneuro.5b00002
- Primary Citation of Related Structures:  
4R3C - PubMed Abstract: 
The first kinase inhibitor drug approval in 2001 initiated a remarkable decade of tyrosine kinase inhibitor drugs for oncology indications, but a void exists for serine/threonine protein kinase inhibitor drugs and central nervous system indications. Stress kinases are of special interest in neurological and neuropsychiatric disorders due to their involvement in synaptic dysfunction and complex disease susceptibility ...